[Prophylaxis and therapy of hepatitis B after liver transplantation].
About 25% of all liver transplantations in USA are performed for liver disease due to viral hepatitis, 25% of them related to hepatitis B. It is also known that 90%-100% of transplanted persons with proven replicative stage of hepatitis B [HBeAg (+), HBV DNA (+)] develop reinfection of the transplanted liver in the absence of prophylaxis. This percentage is lower (30%-50%) in patients with nonreplicative stage of infection [HBeAg (-), HBV DNA (-)]. The consequence of most transplant infections is death due to the transplanted organ failure. The prophylaxis of infection is possible, however a combination of intravenous hepatitis B hyperimmune gammaglobulin and lamivudin may be too expensive for some transplantation centers in less developed countries. The aim of this article is to recommend prophylaxis and treatment of recurrent hepatitis B in persons with transplanted liver using data of the Consensus Conference on Hepatitis B in Geneva 2002, Canadian Consensus Group for Hepatitis (CASL) and EASL International Consensus Conference on Hepatitis B that should be available for patients in Croatia.
Bradarić
Nikola
N
Odjel za zarazne bolesti, Klinicka bolnica Split, Split, Hrvatska. nikola.bradaric@st.htnet.hr
D006509:Hepatitis B / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D012008:Recurrence
D007136:Immunoglobulins; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin